HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Am J Physiol Endocrinol Metab 295: E904-E912, 2008. First published August 12, 2008; doi:10.1152/ajpendo.90248.2008
0193-1849/08 $8.00

This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 295/4/E904    most recent 90248.2008v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Bryzgalova, G. Articles by Dahlman-Wright, K. PubMed PubMed Citation Articles by Bryzgalova, G. Articles by Dahlman-Wright, K.

Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen in high-fat diet-fed mice

¹Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm; and ²Department of Biosciences and Nutrition, Karolinska Institute, Huddinge, Sweden

Submitted 22 February 2008 ; accepted in final form 6 August 2008

The high-fat diet (HFD)-fed mouse is a model of obesity, impaired glucose tolerance, and insulin resistance. The main objective of this study was to elucidate the molecular mechanisms underlying the antidiabetogenic and weight-lowering effects of 17β-estradiol (E₂) in this mouse model. C57BL/6 female mice (8 wk old) were fed on a HFD for 10 mo. E₂, given daily (50 µg/kg sc) during the last month of feeding, decreased body weight and markedly improved glucose tolerance and insulin sensitivity. Plasma levels of insulin, leptin, resistin, and adiponectin were decreased. We demonstrated that E₂ treatment decreased the expression of genes encoding resistin and leptin in white adipose tissue (WAT), whereas adiponectin expression was unchanged. Furthermore, in WAT we demonstrated decreased expression levels of sterol regulatory element-binding protein 1c (SREBP1c) and its lipogenic target genes, such as fatty acid synthase and stearoyl-CoA desaturase 1 (SCD1). In the liver, the expression levels of transcription factors such as liver X receptor and SREBP1c were not changed by E₂ treatment, but the expression of the key lipogenic gene SCD1 was reduced. This was accompanied by decreased hepatic triglyceride content. Importantly, E₂ decreased the hepatic expression of glucose-6-phosphatase (G-6-Pase). We conclude that E₂ treatment exerts antidiabetic and antiobesity effects in HFD mice and suggest that this is related to decreased expression of lipogenic genes in WAT and liver and suppression of hepatic expression of G-6-Pase. Decreased plasma levels of resistin probably also play an important role in this context.

glucose tolerance; insulin sensitivity; obesity; lipogenic genes; glucose-6-phosphatase